Project Grant R01OD036239
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $426,250 to Wake Forest University Health Sciences to develop and evaluate a novel positron emission tomography (PET) radiotracer, [11C]TM-N1324, to measure levels of the G-protein coupled receptor GPR39 in rodent models and postmortem human brain tissues of Alzheimer's disease (AD). The project aims to establish the utility of this PET imaging approach for quantifying GPR39, which is implicated...
- This $3.06 million Project Grant, awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, funds a four-year research initiative (August 2025–July 2029) conducted by the University of Wisconsin–Madison. The award supports the development and characterization of a nonhuman primate model of synucleinopathy to investigate the relationship between alpha-synuclein (αSyn)...
- Grant Award Summary Emory University received a $3,048,430 Project Grant award from the National Institute on Aging under the Aging Research program (CFDA 93.866), effective May 15, 2025 through January 31, 2030. The award funds development of a novel positron emission tomography (PET) ligand targeting poly(ADP-ribose) polymerase-1 (PARP1) for in vivo imaging in Alzheimer's disease research. The primary deliverable is a brain-penetrant, PARP1-selective PET imaging agent that will enable...
- This Project Grant award from the National Institutes of Health (NIH) Research Infrastructure Programs (CFDA 93.351) provides $270,428 to TEO Therapeutics Incorporated, a small disadvantaged business, to develop a biomimetic platform for more efficient pharmaceutical drug development in oncology. The key products and services to be delivered include: Refining and testing a proof-of-concept hardware product line for a Shell-Free Quail Xenograft Assay, optimizing throughput and assessing...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $455,009 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop a novel [18F]-labeled amphiphilic PET probe that can cross the blood-brain barrier and track CD206+ microglia/macrophages in Alzheimer's disease. The goal is to create a non-invasive imaging method to detect anti-inflammatory M2-like microglia and macrophages, which play a key role in...
- This Project Grant award, with a total funding amount of $431,750, was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The award is for the development and evaluation of a novel immuno-gene therapy approach using a single-chain fragment variable (scFv) derived from an anti-tau oligomeric complex 1 (TOC1) antibody. The key objectives are to: 1) generate and validate the TOC1-scFv-HaloTag-Proteasome Degradation Signal (PDS)...
- This $823,691 Project Grant award was provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) to investigate the role of immune checkpoints in the central nervous system (CNS) of people living with HIV (PLWH) and their association with HIV-associated neurocognitive disorder (HAND). The research aims to determine the profiles and biological functions of soluble immune checkpoints (sICPs) in the CNS of PLWH and a simian immunodeficiency...
- This $475,369 federal Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to better understand how microglia (the brain's resident macrophages) are programmed by the brain environment following transplantation. The primary awardee, The Trustees of the University of Pennsylvania, will use single-cell RNA and ATAC sequencing to...
- Grant Award Summary Emory University received a Project Grant award of $860,750 from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), effective June 1, 2025, through May 31, 2027. The award funds research to improve the reach and efficacy of adeno-associated virus (AAV)-based gene therapy by utilizing endogenously produced extracellular vesicles (EVs) to transport engineered transgene...
- The Scintillon Institute received a $1,025,015 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective August 11, 2025, with completion targeted for July 31, 2027. The award funds development of a next-generation preclinical NeuroHIV model to advance understanding of how Human Immunodeficiency Virus (HIV-1) affects the central nervous system...
ENHANCING RIGOR AND REPRODUCIBILITY OF TRANSLATIONAL NONHUMAN PRIMATE MODELS FOR GENETIC AND REGENERATIVE THERAPIES - THIS APPLICATION IS SUBMITTED IN RESPONSE TO PAR-23-040 WITH THE GOAL OF INTEGRATING CUTTING-EDGE IN VIVO IMAGING TECHNOLOGIES AND KEY IMMUNOLOGIC ASSESSMENTS TO ENHANCE THE RIGOR AND REPRODUCIBILITY OF TRANSLATIONAL NONHUMAN PRIMATE MODELS FOR GENETIC AND REGENERATIVE THERAPIES. THE PROPOSAL MEETS THE OBJECTIVE OF PAR-23-040, WHICH IS FOCUSED ON "...DEVELOPING AND IMPLEMENTING BROADLY APPLICABLE TECHNOLOGIES, TOOLS, AND RESOURCES FOR...ENHANCING RIGOR, REPRODUCIBILITY, AND TRANSLATABILITY OF ANIMAL RESEARCH". WE WILL SUPPORT TRANSLATIONAL RESEARCH BY INCORPORATING TOTAL-BODY POSITRON EMISSION TOMOGRAPHY (PET) AND CORRELATIVE ASSESSMENTS OF THE IMMUNE SYSTEM. THE INVESTIGATIONS PROPOSED WILL ENHANCE THE RHESUS MONKEY MODEL SYSTEM BY CREATING OR IMPROVING STUDY PROTOCOLS THAT PROVIDE A HIGH LEVEL OF SENSITIVITY AND REPRODUCIBILITY FOR ASSESSMENTS THAT ARE IMPORTANT TO CLINICAL TRANSLATION. THE SPECIFIC AIMS ARE: (1) USE TOTAL-BODY PET IMAGING TO LONGITUDINALLY MONITOR GENE TRANSFER AND BIODISTRIBUTION IN PRECLINICAL STUDIES OF FETAL OR JUVENILE RHESUS MONKEYS FOR CLINICAL TRANSLATION, AND (2) EXPLORE NEW READOUTS OF IMMUNE RESPONSES TO INNOVATIVE THERAPEUTICS IN TISSUE SITES USING T-CELL TRACKING IN TRANSLATIONAL NONHUMAN PRIMATE STUDIES. THESE INVESTIGATIONS WILL ADDRESS RELATIONSHIPS BETWEEN LOCAL T-CELL INFILTRATION AND CIRCULATING IMMUNOPHENOTYPES WITH CORRELATIVE IN VIVO IMAGING, WHICH WILL ENHANCE MODELS AND PROVIDE NEW METHODS TO ASSESS THE PRIMATE IMMUNE SYSTEM. MONITORING INFLAMMATION AND IMMUNITY IN TARGETED AND NON-TARGETED TISSUES IS CRITICALLY IMPORTANT TO ENSURE SAFETY AS NEW THERAPEUTICS TRANSITION TO THE CLINIC FOR A RANGE OF COMMON AND RARE DISEASES. THESE STUDIES WILL PROVIDE PREDICTIVE PROTOCOLS AND TOOLS WHICH WILL INFORM PRECLINICAL AND IND- ENABLING STUDIES FOR FUTURE HUMAN APPLICATIONS ACROSS AGE GROUPS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $781.5k | 7/25/25 | ||
| Not listed | $781.5k | 6/24/24 |